Use of new psychoactive substances to mimic prescription drugs: The trend in France

被引:15
|
作者
Batisse, Anne [1 ]
Eiden, Celine [2 ]
Peyriere, Helene [2 ]
Djezzar, Samira [1 ]
机构
[1] GH Lariboisiere Fernand Widal, St Louis AP HP, Addictovigilance Ctr Paris, Paris, France
[2] Univ Hosp Montpellier, Addictovigilance Ctr Montpellier, Montpellier, France
关键词
Addiction; New psychoactive substances; Designer medecines; Health monitoring; ADDICTOVIGILANCE; ETHYLPHENIDATE; NETWORK;
D O I
10.1016/j.neuro.2020.03.015
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Among the expanding world of New Psychoactive Substances (NPS), Designer Medicines (DM) are designed to mimic psychoactive drugs and might lead to adverse events of various severity. The DM category includes designer benzodiazepines (DB), phenmetrazine, modafinil, methylphenidate analogs, and novel synthetic opioids (NSO). To investigate DM-related complications in France, all data on NPS collected in the French Addictovigilance network database through spontaneous reports (SRs) and the annual survey on deaths related to the abuse of licit and illicit psychoactive substances (DRAMES survey) between 2009 and 2017 were analyzed. From 2009-2017, about 800 cases of NPS-related abuse or somatic complications were reported to the French Addictovigilance Network, including 71 fatal cases (9%). DM use progressively increased over the years, particularly after 2013 (4% of all SRs on NPS in 2011 versus 14 % in 2017). Moreover, DM were implicated in 17 % of NPS-related deaths in France, just after cathinones (43 %) and dissociative drugs (22 %). NSO, DB and phenidate analogs were identified in 42 %, 25 % and 25 % of all DM-related death reports, respectively. DM seem to interest a new target group of users that includes mainly patients and healthy people rather than substance users. The availability on the Internet of compounds mimicking therapeutic drugs is a worrying phenomenon that could lead to their uncontrolled use.
引用
收藏
页码:20 / 24
页数:5
相关论文
共 50 条
  • [31] ANALYTICALLY CONFIRMED PRESENCE OF PSYCHOACTIVE SUBSTANCES, ESPECIALLY NEW PSYCHOACTIVE SUBSTANCES IN A GROUP OF PATIENTS HOSPITALIZED WITH MENTAL AND BEHAVIOURAL DISORDERS DUE TO THE USE OF PSYCHOACTIVE SUBSTANCES DIAGNOSIS
    Engelgardt, Piotr
    Krzyzanowski, Maciej
    Piotrowski, Przemyslaw
    Borkowska-Sztachanska, Malgorzata
    Wasilewska, Agnieszka
    INTERNATIONAL JOURNAL OF OCCUPATIONAL MEDICINE AND ENVIRONMENTAL HEALTH, 2022, 35 (04) : 485 - 495
  • [32] Acting out and psychoactive substances: alcohol, drugs, illicit substances
    Gillet, C
    Polard, E
    Mauduit, N
    Allain, H
    ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2001, 27 (04): : 351 - 359
  • [33] Drugs and crimes: criminological approach to psychoactive substances
    Romani, Oriol
    DISPARIDADES-REVISTA DE ANTROPOLOGIA, 2020, 75 (02):
  • [34] Drugs and crimes: Criminological approach to psychoactive substances
    Molina-Sanchez, Carlos
    EMPIRIA, 2020, (45): : 217 - 222
  • [35] New drugs: Use of everyday substances as substances of abuse
    Ramirez Dominguez, M. D. L. C.
    Prieto Sanchez, I.
    Nunez Caro, M.
    Hernandez Gonzalez, L.
    EUROPEAN PSYCHIATRY, 2016, 33 : S313 - S314
  • [36] New Psychoactive Drugs
    Dolengevich-Segal, Helen
    Rodriguez Salgado, Beatriz
    Gomez-Arnau Ramirez, Jorge
    Sanchez-Mateos, Daniel
    ADICCIONES, 2015, 27 (03) : 231 - 232
  • [37] The new psychoactive substances (NPS)
    Dargan, P. I.
    TOXICOLOGY LETTERS, 2019, 314 : S49 - S49
  • [38] PHARMACOLOGY OF NEW PSYCHOACTIVE SUBSTANCES
    Farre, M.
    Torrens, M.
    E, Papaseit
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 21 - 21
  • [39] Use of psychoactive substances in prison: Results of a study in the Lyon-Corbas prison, France
    Sahajian, F.
    Berger-Vergiat, A.
    Pot, E.
    REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2017, 65 (05): : 361 - 367
  • [40] ABUSE OF PRESCRIPTION AND LICIT PSYCHOACTIVE SUBSTANCES BY THE ELDERLY - ISSUES AND RECOMMENDATIONS
    NARANJO, CA
    HERRMANN, N
    OZDEMIR, V
    BREMNER, KE
    CNS DRUGS, 1995, 4 (03) : 207 - 221